NASDAQ:ICCC

ImmuCell - ICCC Stock Forecast, Price & News

$8.06

-0.09 (-1.10%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $8.00
▼
$8.10
50-Day Range: $7.70
▼
$9.10
52-Week Range: $7.30
▼
$10.96

Volume: 7,798 shs
Average Volume: 10,387 shs
Market Capitalization: $62.41 million

P/E Ratio: 268.76
Dividend Yield: N/A
Price Target: N/A

ImmuCell MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.18% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.08
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$8,000 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.25 out of 5 stars

Medical Sector

1095th out of 1,125 stocks

Diagnostic Substances Industry

17th out of 17 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for ImmuCell.

3.0

Short Interest

Percentage of Shares Shorted
0.18% of the float of ImmuCell has been sold short.
Short Interest Ratio / Days to Cover
ImmuCell has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ImmuCell has recently increased by 32.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ImmuCell does not currently pay a dividend.
Dividend Growth
ImmuCell does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ICCC.

2.8

News and Social Media Coverage

News Sentiment
ImmuCell has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for ImmuCell this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ImmuCell insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.40% of the stock of ImmuCell is held by insiders.
Percentage Held by Institutions
Only 11.94% of the stock of ImmuCell is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of ImmuCell is 268.76, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 126.69.
Price to Earnings Ratio vs. Sector
The P/E ratio of ImmuCell is 268.76, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 123.34.
Price to Book Value per Share Ratio
ImmuCell has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ImmuCell (NASDAQ:ICCC) Stock

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Analyst Upgrades and Downgrades

Separately, Aegis reaffirmed a "buy" rating on shares of ImmuCell in a research note on Thursday, June 23rd.

ImmuCell Stock Down 6.9 %

ICCC traded down $0.60 during trading hours on Monday, hitting $8.15. 3 shares of the company's stock were exchanged, compared to its average volume of 10,404. ImmuCell has a 12-month low of $7.30 and a 12-month high of $10.96. The firm has a 50 day moving average of $8.50 and a 200 day moving average of $8.64. The firm has a market cap of $63.11 million, a P/E ratio of 271.76 and a beta of 0.58. The company has a current ratio of 6.91, a quick ratio of 5.07 and a debt-to-equity ratio of 0.30.

ImmuCell (NASDAQ:ICCC - Get Rating) last announced its quarterly earnings data on Thursday, May 12th. The biotechnology company reported $0.09 EPS for the quarter. ImmuCell had a net margin of 1.34% and a return on equity of 0.84%. The company had revenue of $6.00 million for the quarter.

Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

ICCC Stock News Headlines

August 11, 2022 | finance.yahoo.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022

August 10, 2022 | americanbankingnews.com

ImmuCell (ICCC) to Release Quarterly Earnings on Thursday

August 5, 2022 | finance.yahoo.com

Does ImmuCell (NASDAQ:ICCC) Have A Healthy Balance Sheet?

August 4, 2022 | finance.yahoo.com

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022

July 27, 2022 | finance.yahoo.com

ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®

July 7, 2022 | finance.yahoo.com

ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022

June 15, 2022 | finance.yahoo.com

Is ImmuCell Corporation's (NASDAQ:ICCC) Stock Price Struggling As A Result Of Its Mixed Financials?

May 28, 2022 | uk.finance.yahoo.com

Sixteen further monkeypox cases detected in England, UK Health Security Agency confirms - Yahoo Finance UK

May 17, 2022 | finance.yahoo.com

The Secret Ingredient: A Winning Strategy in 2022 - Yahoo Finance

May 16, 2022 | finance.yahoo.com

ImmuCell's (NASDAQ:ICCC) investors will be pleased with their respectable 35% return over the last five years

May 15, 2022 | seekingalpha.com

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2022 Results - Earnings Call Transcript

May 12, 2022 | globenewswire.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022 - GlobeNewswire

May 12, 2022 | finance.yahoo.com

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022

May 11, 2022 | globenewswire.com

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022 - GlobeNewswire

May 10, 2022 | benzinga.com

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022 - Benzinga - Benzinga

May 10, 2022 | finance.yahoo.com

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022

May 6, 2022 | finance.yahoo.com

Alpha Copper Increases 2022 Budget for Indata Copper-Gold Project - Yahoo Finance

May 5, 2022 | globenewswire.com

Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement - GlobeNewswire

May 5, 2022 | finance.yahoo.com

Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement

May 5, 2022 | finance.yahoo.com

UPDATE -- Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement

April 27, 2022 | uk.investing.com

60 Biggest Movers From Yesterday By Benzinga - Investing.com UK

April 13, 2022 | benzinga.com

ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022 - Benzinga - Benzinga

April 12, 2022 | globenewswire.com

Veterinary Therapeutics Market to Reach US$ 58.5 Bn by 2027, notes TMR Study - GlobeNewswire

April 12, 2022 | streetinsider.com

Form PRE 14A IMMUCELL CORP /DE/ For: Apr 12 - StreetInsider.com

April 11, 2022 | globenewswire.com

ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022 - GlobeNewswire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

ICCC Company Calendar

Last Earnings: 8/12/2021
Today: 8/15/2022
Next Earnings (Estimated): 11/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ICCC
CUSIP: N/A
CIK: 811641
Web: www.immucell.com
Phone: (207) 878-2770
Fax: 207-878-2117
Employees: 60
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.03
Trailing P/E Ratio: 268.76
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-80,000.00
Net Margins: 1.34%
Pretax Margin: 1.39%
Return on Equity: 0.84%
Return on Assets: 0.60%

Debt

Debt-to-Equity Ratio: 0.30
Current Ratio: 6.91
Quick Ratio: 5.07

Sales & Book Value

Annual Sales: $19.24 million
Price / Sales: 3.24
Cash Flow: $0.31 per share
Price / Cash Flow: 26.39
Book Value: $4.21 per share
Price / Book: 1.91

Miscellaneous

Outstanding Shares: 7,743,000
Free Float: 7,251,000
Market Cap: $62.41 million
Optionable: Not Optionable
Beta: 0.58

Key Executives

Mr. Michael F. Brigham (Age 61)
Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director
Comp: $359.59k
Ms. Bobbi Jo Brockmann (Age 45)
VP of Sales & Marketing and Director
Comp: $299.58k
Ms. Elizabeth L. Williams (Age 66)
VP of Manufacturing Operations
Comp: $265.12k
Elizabeth S. Toothaker
Director of Fin. & Admin.
Mr. A. Gustavo Scaffa
Sr. Director of Quality
John W. Zinckgraf
Director of Product Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ICCC Stock - Frequently Asked Questions

Should I buy or sell ImmuCell stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICCC shares.
View ICCC analyst ratings or view top-rated stocks.
How have ICCC shares performed in 2022?: ImmuCell's stock was trading at $8.0001 on January 1st, 2022. Since then, ICCC shares have increased by 0.7% and is now trading at $8.06.
View the best growth stocks for 2022 here.
When is ImmuCell's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our ICCC earnings forecast.
How were ImmuCell's earnings last quarter?: ImmuCell Co. (NASDAQ:ICCC) posted its earnings results on Thursday, August, 12th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.10. The biotechnology company earned $4.54 million during the quarter. ImmuCell had a net margin of 1.34% and a trailing twelve-month return on equity of 0.84%.
What guidance has ImmuCell issued on next quarter's earnings?: ImmuCell issued an update on its second quarter 2022 earnings guidance on Thursday, July, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.90 million-$3.90 million.

What other stocks do shareholders of ImmuCell own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CorMedix (CRMD), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).
What is ImmuCell's stock symbol?: ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."
Who are ImmuCell's major shareholders?: ImmuCell's stock is owned by a number of retail and institutional investors. Top institutional investors include Overbrook Management Corp (0.46%). Insiders that own company stock include David Cunningham and David Scott Tomsche.
View institutional ownership trends.
How do I buy shares of ImmuCell?: Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ImmuCell's stock price today?: One share of ICCC stock can currently be purchased for approximately $8.06.
How much money does ImmuCell make?: ImmuCell (NASDAQ:ICCC) has a market capitalization of $62.41 million and generates $19.24 million in revenue each year. The biotechnology company earns $-80,000.00 in net income (profit) each year or $0.03 on an earnings per share basis.
How can I contact ImmuCell?: ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The official website for the company is www.immucell.com. The biotechnology company can be reached via phone at (207) 878-2770, via email at iccc@lythampartners.com, or via fax at 207-878-2117.

This page (NASDAQ:ICCC) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

ImmuCell - ICCC Stock Forecast, Price & News

ImmuCell MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month